5324882026-01-012026-03-315324882026-03-315324882025-03-315324882025-04-012026-03-315324882026-01-012026-03-31in-capmkt:OtherExpenses1Member5324882025-04-012026-03-31in-capmkt:OtherExpenses1Member5324882026-03-31OtherNoncurrentFinancialAssetsDomain15324882026-03-31OtherNoncurrentAssetsDomain15324882026-03-31OtherCurrentFinancialAssetsDomain15324882026-03-31OtherCurrentAssetsDomain15324882026-03-31OtherNoncurrentFinancialLiabilitiesDomain15324882026-03-31OtherNoncurrentLiabilitiesDomain15324882026-03-31OtherCurrentFinancialLiabilitiesDomain15324882026-03-31OtherCurrentLiabilitiesDomain15324882026-01-012026-03-31ItemsThatWillNotBeReclassifiedToProfitAndLoss15324882025-04-012026-03-31ItemsThatWillNotBeReclassifiedToProfitAndLoss15324882026-01-012026-03-31RelatedPartyTransactionDomain15324882025-12-31RelatedPartyTransactionDomain15324882026-03-31RelatedPartyTransactionDomain15324882026-01-012026-03-31RelatedPartyTransactionDomain25324882025-12-31RelatedPartyTransactionDomain25324882026-03-31RelatedPartyTransactionDomain25324882026-01-012026-03-31RelatedPartyTransactionDomain35324882025-12-31RelatedPartyTransactionDomain35324882026-03-31RelatedPartyTransactionDomain35324882026-01-012026-03-31RelatedPartyTransactionDomain45324882025-12-31RelatedPartyTransactionDomain45324882026-03-31RelatedPartyTransactionDomain45324882026-01-012026-03-31RelatedPartyTransactionDomain55324882025-12-31RelatedPartyTransactionDomain55324882026-03-31RelatedPartyTransactionDomain55324882026-01-012026-03-31RelatedPartyTransactionDomain65324882025-12-31RelatedPartyTransactionDomain65324882026-03-31RelatedPartyTransactionDomain65324882026-01-012026-03-31RelatedPartyTransactionDomain75324882025-12-31RelatedPartyTransactionDomain75324882026-03-31RelatedPartyTransactionDomain75324882026-01-012026-03-31RelatedPartyTransactionDomain85324882025-12-31RelatedPartyTransactionDomain85324882026-03-31RelatedPartyTransactionDomain85324882026-01-012026-03-31RelatedPartyTransactionDomain95324882025-12-31RelatedPartyTransactionDomain95324882026-03-31RelatedPartyTransactionDomain95324882026-01-012026-03-31RelatedPartyTransactionDomain105324882025-12-31RelatedPartyTransactionDomain105324882026-03-31RelatedPartyTransactionDomain105324882026-01-012026-03-31RelatedPartyTransactionDomain115324882025-12-31RelatedPartyTransactionDomain115324882026-03-31RelatedPartyTransactionDomain115324882026-01-012026-03-31RelatedPartyTransactionDomain125324882025-12-31RelatedPartyTransactionDomain125324882026-03-31RelatedPartyTransactionDomain125324882026-01-012026-03-31RelatedPartyTransactionDomain135324882025-12-31RelatedPartyTransactionDomain135324882026-03-31RelatedPartyTransactionDomain135324882026-01-012026-03-31RelatedPartyTransactionDomain145324882025-12-31RelatedPartyTransactionDomain145324882026-03-31RelatedPartyTransactionDomain145324882026-01-012026-03-31RelatedPartyTransactionDomain155324882025-12-31RelatedPartyTransactionDomain155324882026-03-31RelatedPartyTransactionDomain155324882026-01-012026-03-31RelatedPartyTransactionDomain165324882025-12-31RelatedPartyTransactionDomain165324882026-03-31RelatedPartyTransactionDomain165324882026-01-012026-03-31RelatedPartyTransactionDomain175324882025-12-31RelatedPartyTransactionDomain175324882026-03-31RelatedPartyTransactionDomain175324882026-01-012026-03-31AuditorDomain1iso4217:INRiso4217:INRxbrli:shares532488DIVISLABNOTLISTEDINE361B01024Divi's Laboratories LimitedMain BoardEquity2025-04-012026-03-312026-05-232026-05-14INRCroresQuarterlyFourth quarterSingle segmentManufacture of Active Pharmaceutical Ingredients, Intermediates and Nutraceutical Ingredients2026-05-2310:15:002026-05-2311:50:00trueCash Flow IndirectDeclaration of unmodified opiniontruetrueNANAfalsetrue2025-02-03https://www.divislabs.com/wp-content/uploads/2025/07/Policy-on-Related-Party-Transactions.pdffalsefalseNot Applicable2026-01-012026-03-31AuditedStandalone27930000000154000000029470000000117300000000-70000000037000000006000000012000000003770000000197600000009710000000097100000002500000000-35000000021500000000756000000000007560000000-600000007500000000530000000228.4428.440028.4428.44 <BR> 1. The above Statement of standalone audited financial results for the quarter and year ended March 31, 2026, Standalone audited statement of assets and liabilities and Standalone audited statement of cash flows as at and for the year ended March 31, 2026 (Standalone statements) are prepared in accordance with the recognition and measurement principles laid down in applicable Indian Accounting Standards (lnd AS) prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended. The Standalone statements have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on May 23, 2026. The statutory auditors have audited the standalone statements and issued an unmodified report thereon. <BR> 2. The Company is engaged in the manufacture of Active Pharmaceutical Ingredients, intermediates and nutraceutical ingredients; and the same constitutes a single reportable business segment as per Ind AS 108. <BR> 3. The Company does not have any discontinued operations and the Profit for the year represents the Profits from continuing operations only. <BR> 4. On November 21, 2025, the Government of India notified the four labour codes viz., the Code on Wages, 2019, the Industrial Relations Code, 2020, the Code on Social Security, 2020 and the Occupational Safety, Health and Working Conditions Code, 2020, (Labour Codes) consolidating twenty nine existing labour laws. The Ministry of Labour and Employment notified central rules and issued FAQs to enable assessment of the financial impact due to changes in regulations. The Company has assessed the impact based on the best available information and recognised the incremental impact of employee benefits expense of Rs.74 crores. The said incremental impact primarily arises due to change in the definition of wages and the same has been accounted in accordance with the applicable accounting standards. Considering its non-recurring nature and amount involved, such incremental impact is presented under Exceptional items in the Standalone statements. The Company continues to monitor the developments pertaining to implementation of Labour Codes and will provide the appropriate impact in accordance with applicable accounting standards, if any. <BR> 5. Financial results for the quarter ended March 31, 2026 and corresponding quarter ended March 31, 2025 are the balancing figures between audited figures in respect of the full financial year and the unaudited published year-to-date figures up to the third quarter of the respective financial years, which were subject to limited review. <BR> 6. The Board of Directors of the Company has recommended a dividend of Rs. 30 per share of face value Rs. 2 each i.e. 1500 percentage for the financial year 2025 26, subject to approval of members at the ensuing annual general meeting. <BR> 7. Forex gain included in Other Income for the respective periods is as given below <BR> (Rs in Crores) <BR> Quarter ended Year Ended <BR> 31.03.2026 31.12.2025 31.03.2025 31.03.2026 31.03.2025 <BR> (Audited) (Unaudited) (Audited) (Audited) (Audited) <BR> Forex gain 89 18 11 210 48 <BR> 2025-04-012026-03-31AuditedStandalone1038800000005060000000108940000000426000000000-2440000000140000000002300000004610000000148400000007384000000035100000000-740000000343600000008690000000-40000000082900000000260700000000000260700000006000000026130000000530000000216658000000098.1998.190098.1998.19Other Expenses3770000000Other Expenses14840000000651400000002113000000006000000076000000006700000001430000000144000000089200000000371100000000322800000008500000003286000000008000000066070000000716000000011034000000019954000000053000000016658000000016711000000016711000000004560000000456000000081000000046900000002180000000122400000000620000000112800000001190000000046000000001650000000029800000006000000001100000002019000000032430000000199540000000Other non-current financial assets670000000Other non-current assets1440000000Other current financial assets80000000Other current assets7160000000Other non-current financial liabilities4560000000Other non-current liabilities2180000000Other current financial liabilities4600000000Other current liabilities2980000000230000000-6780000000-261000000000-3340000000300000000030300000000044000000004610000000010000000057300000000-1060000000028400000000-4000000000000137000000035730000000000862000000002711000000000000000300000002519000000000000000000000000028400000000140000000-221800000000000000000079700000005000000000-8020000000-30900000000-30900000003940000000850000000Gain/loss on Remeasurement of post-employment benefit obligations-80000000-80000000Gain/loss on Remeasurement of post-employment benefit obligations8000000080000000-2000000020000000-6000000060000000Divi's Laboratories Limited******Dr. Murali. K. Divi******Key Management PersonnelRemunerationAs per the Companies Act, 2013 / approval of Board of Directors or shareholders according to the statutory requirment.525500000475500000999000000Divi's Laboratories Limited******Dr. Kiran S. Divi******Key Management PersonnelRemunerationAs per the Companies Act, 2013 / approval of Board of Directors or shareholders according to the statutory requirment.182300000159000000333500000Divi's Laboratories Limited******Ms. Nilima Prasad Divi******Key Management PersonnelRemunerationAs per the Companies Act, 2013 / approval of Board of Directors or shareholders according to the statutory requirment.182300000159000000333500000Divi's Laboratories Limited******Mr. N.V.Anirudh******Relative of Key Management PersonnelRemuneration4900000Not Applicable4900000400000700000Divi's Laboratories Limited******Mr Swaroop Krishna Sureddi******Relative of Key Management PersonnelRemuneration2900000Not Applicable29000002000001100000Divi's Laboratories Limited******Divi’s Properties Private Limited******Entities in which Key Management Personnel have Significant InfluenceAny other transactionRent for Premises68100000Not Applicable6810000000Divi's Laboratories Limited******Divi’s Biotech Private Limited******Entities in which Key Management Personnel have Significant InfluenceAny other transactionRent for Premises900000Not Applicable90000000Divi's Laboratories Limited******Divi’s Properties Private Limited******Entities in which Key Management Personnel have Significant InfluenceAny other transactionRent Deposit34200000Not Applicable03420000034200000Divi's Laboratories Limited******Divis Laboratories (USA) Inc******Subsidiary CompanySale of goods or servicesNot Applicable1255900000858300000939600000Divi's Laboratories Limited******Divi's Laboratories Europe AG******Subsidiary CompanySale of goods or servicesNot Applicable142660000028418000003443700000Divis Laboratories (USA) Inc******Divi's Laboratories Europe AG******Subsidiaries of Divi's Laboratories LimitedSale of goods or servicesNot Applicable-142000001500000600000Divi's Laboratories Europe AG******Divis Laboratories (USA) Inc******Subsidiaries of Divi's Laboratories LimitedSale of goods or servicesNot Applicable1616000009500000102700000Divi's Laboratories Limited******Divi's Foundation For Gifted Children******Other Related PartyAny other transactionContribution for CSR Project Implementation61000000Not Applicable1200000000Divi's Laboratories Limited******Sri Lakshmi Constructions******Entities in which Key Management Personnel have Significant InfluencePurchase of goods or services600000000Not Applicable2322000003230000069900000Divi's Laboratories Limited******Sri Lakshmi Constructions******Entities in which Key Management Personnel have Significant InfluenceAny other transactionAdvance for Purchase of Goods and Services600000000Not Applicable11400000037600000200000Divi's Laboratories Limited******Bheema Infra Solutions Private Limited******Entities in which Key Management Personnel have Significant InfluencePurchase of goods or services100000000Not Applicable54000000190000020200000Divi's Laboratories Limited******Bheema Infra Solutions Private Limited******Entities in which Key Management Personnel have Significant InfluenceAny other transactionAdvance for Purchase of Goods and Services100000000Not Applicable02070000004209000000AuditedtruePrice Waterhouse Chartered Accountants LLPtrue2026-11-30